AstraZeneca dumps Targacept's antidepressant TC-5214 after two more Ph III failures
AstraZeneca has decided to cut its losses and drop the Phase III antidepressant candidate TC-5214 that it licensed from Targacept in December 2009.
AstraZeneca has decided to cut its losses and drop the Phase III antidepressant candidate TC-5214 that it licensed from Targacept in December 2009.